Three mRNA designs for diverse projects. TriLink offers premade mRNAs in three designs: CleanCap® mRNAs, CleanCap mRNAs (5moU), and CleanCap M6 mRNAs (N1MePsU). They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability.
Their 5′ UTR is synthetic, containing a strong Kozak sequence, designed to promote efficient translation while the 3′ UTR is derived from mouse alpha-globin. Their key differences lie in the type of CleanCap analog used and the base compositions, which may affect their protein expression and immunogenicity. View the three TriLink CleanCap options in the table below.
Six new CleanCap mRNA constructs
The new constructs are available in three sizes (100 µg, 1 mg, 5 mg) and bulk. These constructs are listed in the table below.
TriLink mRNA workflow solutions
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organisation (CDMO) for the synthesis of nucleic acids, NTPs and mRNA capping analogs. TriLink has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Learn more about the Trilink’s mRNAs
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
